

Cover Story
Free
By Matthew Bin Han Ong
Joyce Shoffner would never have predicted that Duke University, an institution she revered and at one time worked for, would put her in a breast cancer clinical trial testing a fraudulent technology.
In Brief
Drugs & Targets
Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Pam Bondi diagnosed with thyroid cancer
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer












